Bio-Rad Laboratories, Inc. (NYSE:BIO) has received an average recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $260.00.

A number of equities research analysts have commented on BIO shares. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, October 12th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $255.00 target price on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. Finally, TheStreet downgraded shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd.

Bio-Rad Laboratories (NYSE:BIO) traded down $0.83 during trading hours on Wednesday, reaching $255.49. 129,090 shares of the company’s stock were exchanged, compared to its average volume of 194,172. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.77 and a current ratio of 4.06. Bio-Rad Laboratories has a fifty-two week low of $169.18 and a fifty-two week high of $268.40. The company has a market cap of $8,890.00, a P/E ratio of 80.39, a PEG ratio of 3.82 and a beta of 0.88.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, November 2nd. The medical research company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.37. Bio-Rad Laboratories had a net margin of 1.15% and a return on equity of 3.44%. The business had revenue of $535.00 million during the quarter, compared to the consensus estimate of $507.99 million. During the same quarter in the previous year, the firm posted $0.62 EPS. The firm’s revenue was up 5.2% on a year-over-year basis. equities analysts predict that Bio-Rad Laboratories will post 2.65 earnings per share for the current year.

In other news, EVP Giovanni Magni sold 2,400 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $253.01, for a total transaction of $607,224.00. Following the completion of the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $2,340,595.51. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 28.29% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC bought a new stake in shares of Bio-Rad Laboratories during the 2nd quarter valued at $7,584,000. Capital Analysts LLC bought a new stake in shares of Bio-Rad Laboratories during the 2nd quarter valued at $170,000. BNP Paribas Arbitrage SA grew its position in shares of Bio-Rad Laboratories by 63.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,882 shares of the medical research company’s stock valued at $1,784,000 after acquiring an additional 3,047 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of Bio-Rad Laboratories by 1.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 115,218 shares of the medical research company’s stock valued at $26,075,000 after acquiring an additional 2,070 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Bio-Rad Laboratories by 16.1% during the 2nd quarter. Legal & General Group Plc now owns 22,419 shares of the medical research company’s stock valued at $5,074,000 after acquiring an additional 3,107 shares during the period. 64.27% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/18/bio-rad-laboratories-inc-bio-receives-260-00-average-target-price-from-brokerages.html.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Stock Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related stocks with our FREE daily email newsletter.